Pliant Therapeutics to present PLN-101095 trial data at ASCO meeting
PUBT · 05/21 21:29
Share
Listen to the news
- Pliant Therapeutics will present data on PLN-101095 in combination with pembrolizumab at the ASCO Annual Meeting in Chicago, May 29 to June 2, 2026.
- The poster is scheduled for Saturday, May 30, 2026, 1:30 p.m. to 4:30 p.m. Central Time, in the Developmental Therapeutics – Immunotherapy session.
- The presentation focuses on cohort expansion from the Phase 1 study in patients with advanced solid tumors refractory to immune checkpoint inhibitors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211729PRIMZONEFULLFEED9725072) on May 21, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved